期刊
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
卷 94, 期 12, 页码 1758-1761出版社
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2009.010496
关键词
hyperlipasemia; hyperamylasemia; pancreatic enzymes; chronic myeloid leukemia; imatinib; nilotinib
类别
资金
- European LeukemiaNet funds
- Italian Association for Cancer Research
- COFIN
- BolognAIL
An increase in the serum concentration of pancreatic enzymes (amylase and lipase) was reported in a proportion of imatinib-resistant and/or intolerant Philadelphia-positive chronic myeloid leukemia patients treated with nilotinib. Acute pancreatitis was very rare, and the relevance of these laboratory alterations remains unknown. We report on 8 chronic myeloid leukemia patients who developed serum lipase/amylase elevation during treatment with nilotinib. After a median follow-up of 26 months, none of these patients developed an acute pancreatitis or clinical signs of pancreatic disease. Pancreatic hyperenzymemia never led to permanent drug discontinuation and required nilotinib temporary interruption in one case only. The median cumulative duration of dose interruptions and response to treatment were comparable in patients with or without pancreatic enzyme elevation. The mechanisms of action of nilotinib on pancreatic enzymes deserves to be investigated: however, in our experience, the relevance of pancreatic hyperenzymemia was clinically very limited.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据